162 episodes

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

PeerView Heart, Lung & Blood CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

    • video
    Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

    Minetta C. Liu, MD - Innovative Blood-Based Screening in Cancer Care: State of the Science and Future Opportunities for Accelerating Cancer Diagnoses

    Go online to PeerView.com/ZKC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology and respiratory medicine share insights on how to best integrate novel blood-based cancer diagnostic technologies into clinical practice in order to facilitate timely diagnosis and treatment initiation.Upon completion of this activity, participants will be able to: Review the scientific principles of liquid biopsy as a tool for cancer diagnosis, including relevant biomarkers, as well as strengths and limitations compared with conventional diagnostic techniques, Describe the role and clinical implications of emerging blood-based diagnostic aids for cancer in secondary and tertiary care settings, Adapt current diagnostic workflows for cancer based on recent evidence on emerging blood-based diagnostic tests in an effort to expedite cancer discovery and subsequent treatment, Apply a patient-centered approach to the diagnosis and transition of care for patients with cancer, including educating patients on potential blood-based testing options.

    • 27 min
    • video
    Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

    Roy S. Herbst, MD, PhD & Lecia V. Sequist, MD, MPH - New Milestones and Changing Standards of Care in EGFR-Mutated NSCLC: Expanding the Benefits of Genomic Testing and EGFR-Targeted Therapy to Early-Stage Lung Cancer

    Go online to PeerView.com/KFC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Advances in the management of patients with EGFR-mutated non-small cell lung cancer (NSCLC) have set a precedent for precision medicine. Genomic testing for EGFR mutations and use of EGFR-targeted therapies in appropriate patients have had an established role in the metastatic setting for many years, and they have recently expanded to early-stage disease. Based on impressive data, the FDA granted approval for the first EGFR tyrosine kinase inhibitor as adjuvant therapy following tumor resection in patients with NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. This approval has effectively changed the standard of care in the early-stage setting, with implications for the practice of the entire multidisciplinary team. This PeerView Live educational activity based on a recent web broadcast provides expert insights on the latest data and useful guidance for navigating the controversies, complexities of decision-making, and practicalities of multidisciplinary collaboration related to EGFR testing and EGFR-targeted therapy in early-stage NSCLC. Upon completion of this activity, participants should be better able to: Discuss the molecular heterogeneity of NSCLC and the oncogenic drivers such as EGFR mutations that help to inform treatment decisions regarding targeted therapies, Evaluate the latest safety and efficacy data on EGFR-targeted therapies in patients with early-stage EGFR-mutated NSCLC, Describe the evolving evidence and best practices for EGFR testing in lung cancer, including in early-stage NSCLC, Collaborate with the multidisciplinary team to integrate EGFR-targeted therapy into treatment plans for eligible patients with EGFR-mutated NSCLC, including in the adjuvant setting, according to recent evidence, precision oncology principles, and patient needs and preferences.

    • 1 hr 3 min
    Khaldoun G. Tarakji, MD, MPH - Adopting Telemedicine and Digital Tools for Nonvalvular Atrial Fibrillation Management and Stroke Prevention

    Khaldoun G. Tarakji, MD, MPH - Adopting Telemedicine and Digital Tools for Nonvalvular Atrial Fibrillation Management and Stroke Prevention

    Go online to PeerView.com/TWX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two experts in cardiovascular medicine discuss the benefits of telemedicine when screening and caring for patients with nonvalvular atrial fibrillation (NVAF). Upon completion of this activity, participants will be able to: Identify the benefits of using telemedicine and remote care services to diagnose and manage patients with NVAF, Describe ways in which telemedicine and remote care services can be used to increase patient awareness about the risks of NVAF and overcome healthcare disparities to improve healthcare delivery for patients with untreated NVAF, Operationalize best practices to design processes and procedures for a telemedicine or remote care program to manage patients with NVAF and prevent stroke, Employ telemedicine and remote care services to diagnose and manage patients with NVAF during the COVID-19 pandemic and beyond.

    • 1 hr 28 min
    • video
    Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

    Gail J. Roboz, MD / James M. Foran, MD, FRCPC - Charting Progress in AML Care: A Clinical CaseBook on the Intersection of Novel Therapy and Allogeneic HCT

    Go online to PeerView.com/UPA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in acute myeloid leukemia (AML) present sample cases that demonstrate clinical problems, challenges, and decision points for hematopoietic stem cell transplant–eligible patients with AML, as well as scientific lectures that highlight the management role of novel therapeutics across a wide range of AML treatment settings. Upon completion of this activity, participants should be better able to: Describe current guidelines for transplant eligibility and the use of novel therapeutics as induction, pretransplant conditioning, or post-HCT maintenance for AML, Discuss safety and efficacy evidence related to innovative approaches to induction, conditioning, and maintenance therapy in conjunction with allogeneic HCT in AML, including strategies using newer cytotoxic agents, targeted agents, antibodies, and epigenetic therapies, Select evidence-based regimens with novel components for use in conjunction with allogeneic HCT in the AML setting.

    • 59 min
    • video
    Stella Lee, MD - Improving the Management of Chronic Rhinosinusitis With Nasal Polyps: Practical Strategies for Selecting the Right Patients for Targeted Treatment

    Stella Lee, MD - Improving the Management of Chronic Rhinosinusitis With Nasal Polyps: Practical Strategies for Selecting the Right Patients for Targeted Treatment

    Go online to PeerView.com/ERM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in chronic rhinosinusitis with nasal polyps (CRS/NP) discusses how to diagnose and manage CRS/NP; identifies patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy; and discusses treatment plans for patients with CRS/NP according to international consensus statements and the latest clinical evidence as part of a multidisciplinary approach. Upon completion of this activity, participants should be better able to: Describe the burden that chronic rhinosinusitis with nasal polyps (CRS/NP), including certain treatment measures, such as surgery, may have on patient quality of life, Identify patients with severe, inadequately controlled CRS/NP to determine eligibility for targeted biologic therapy, Develop treatment plans for patients with CRS/NP according to practice guidelines and the latest clinical evidence as part of a multidisciplinary approach.

    • 35 min
    • video
    Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes

    Stephen V. Liu, MD - Changing the Game for Patients With ES-SCLC Through Multidisciplinary Collaboration: Best Practices to Optimize Immunotherapy-Based Approaches and Improve Patient Outcomes

    Go online to PeerView.com/MSE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Small cell lung cancer (SCLC) is an aggressive form of lung cancer that lacked treatment advances for more than three decades. Fortunately, immune checkpoint inhibitors have recently revolutionized the extensive-stage (ES) SCLC treatment landscape, and combination chemoimmunotherapy has become the new standard of care in the first-line setting. Research efforts are continuing to refine and expand the role of immunotherapies in SCLC. To make the most of this novel therapeutic approach, it is essential for oncology professionals as well as the broader multidisciplinary team of professionals to keep up with the latest therapeutic advances and collaborate effectively to establish the diagnosis, ensure a rapid initiation of therapy, and appropriately manage potential immune-related adverse events. This accredited PeerView on-demand activity is based on a virtual meeting that utilized the innovative Pando™ platform. Leading experts provide an engaging educational session on the latest science, best practices, and multidisciplinary implications related to integrating cancer immunotherapies into the management plans for patients with ES-SCLC. Upon completion of this activity, participants will be able to: Describe the epidemiology, clinical features, and current treatment of extensive-stage small cell lung cancer (ES-SCLC), including immunotherapies that can improve long-term outcomes, Examine the latest efficacy, safety, and biomarker data from clinical trials evaluating available and emerging immunotherapies and immune-based combinations for ES-SCLC, Implement optimal strategies for screening, diagnosing, and staging of patients with lung cancer to ensure timely and accurate diagnosis, prompt oncology referral, and rapid treatment initiation for patients with ES-SCLC, Apply best practices for collaboration and coordination of care with oncologists and other members of the multidisciplinary lung cancer team to provide optimal care to patients with ES-SCLC, including the integration of immunotherapies into treatment plans and recognition/management of irAEs, and improve outcomes.

    • 1 hr 3 min

Top Podcasts In Science

Listeners Also Subscribed To